TABLE 5

Sensitivity analysis in EpiHealth

Protein	Abbreviation	UniProtNo	EpiHealth^#		EpiHealth^¶
			FVC % preicted		FVC % predicted
			β-coefficient (95% CI)	Adjusted p-value	β-coefficient (95% CI)	Adjusted p-value
Leptin	LEP	P41159	−5.31 (−6.40– −4.22)	6.8×10⁻¹⁹	−4.64 (−5.7– −3.58)	5.1×10⁻¹⁵
Paraoxonase 3	PON3	Q15166	2.17 (1.41–2.93)	3.4×10⁻⁰⁶	1.52 (0.65–2.39)	0.013
Fatty acid-binding protein 4	FAB4	P15090	−2.35 (−3.27– −1.43)	2.6×10⁻⁰⁵	−2.93 (−3.93– −1.93)	1.3×10⁻⁶
Interleukin-6	IL-6	P05231	−1.34 (−2.04– −0.64)	0.003	−1.35 (−2.14– −0.56)	0.015
Insulin-like growth factor-binding protein 2	IGFBP2	P18065	1.66 (0.91–2.42)	0.001	1.37 (0.51–2.23)	0.02
Interleukin-1 receptor antagonist protein	IL-1RA	P18510	−1.55 (−2.35– −0.76)	0.003	−1.78 (−2.73– −0.83)	0.007
Receptor for advanced glycosylation and products	RAGE	Q15109	0.97 (0.30–1.65)	0.05	0.95 (0.17–1.73)	0.1⁺
Agouti-related protein	AGRP	O00253	1.19 (0.51–1.87)	0.008	1.07 (0.27–1.86)	0.07⁺
Fibroblast growth factor 21	FGF21	Q9NSA1	−1.02 (−1.71– −0.31)	0.05	−1.27 (−2.08– −0.46)	0.03
Kidney injury molecule	KIM1	Q96D42	−1.40 (−2.11– −0.68)	0.0028	−1.59 (−2.44– −0.73)	0.008
Retinoic acid receptor responder 2	RARRES2	Q99969	−1.96 (−2.70– −1.22)	1.2×10⁻⁵	−2.07 (−2.88–1.26)	4.4×10⁻⁵
Hydroxyacid oxidase 1	HAOX1	Q9UJM8	−1.41 (−2.08– −0.73)	0.001	−1.33 (−2.11– −0.55)	0.015
C-C motif chemokine 16	CCL16	O15467	−1.46 (−2.16– −0.76)	0.001	−1.31 (−2.09– −0.53)	0.02
Insulin-like growth factor-binding protein 1	IGFBP1	P08833	1.53 (0.75–2.30)	0.0027	1.59 (0.72–2.47)	0.008
Plasminogen activator inhibitor	PAI	P05121	−1.28 (−1.95– −0.60)	0.0035	−1.16 (−1.93– −0.39)	0.04
Tissue-type plasminogen activator	tPA	P00750	−1.41 (−2.15– −0.68)	0.003	−1.59 (−2.41– −0.76)	0.007
Growth hormone	GH	P01241	1.24 (0.45–2.02)	0.025	1.53 (0.62–2.45)	0.02
C-C motif chemokine 17	CCL17	Q92583	−1.03 (−1.70– −0.36)	0.03	−1.09 (−1.86– −0.33)	0.052⁺
C-C motif chemokine 3	CCL3	P10147	−1.02 (−1.71– −0.33)	0.04	−1.22 (−2.08– −0.35)	0.06⁺
Matrix metalloproteinase 7	MMP7	P09237	−1.34 (−2.06– −0.62)	0.0043	−1.18 (−2.05– −0.32)	0.06⁺
Adhesion G protein-coupled receptor G2	ADGRG2	Q8IZP9	1.89 (1.19–2.59)	1.0×10⁻⁵	1.79 (0.97–2.59)	0.0006
Thrombospondin-2	THBS2	P35442	−1.02 (−1.68– −0.36)	0.03	−1.0 (−1.8– −0.19)	0.1⁺
Spondin-2	SPON2	Q9BUD6	−1.15 (−1.83– −0.46)	0.013	−1.49 (−2.27– −0.7)	0.007
Adrenomedullin	ADM	P35318	−1.91 (−2.70– −1.12)	9.5×10⁻⁵	−2.14 (−3.07– −1.21)	0.0004
Angiopoietin Like 1	ANGPTL1	O95841	0.74 (0.07–1.4)	0.18⁺	31 (0.54–2–08)	0.01
Tumour necrosis factor receptor 2	TNFR2	P20333	−0.87 (−1.59– −0.14)	0.13⁺	−1.25 (−2.04–−0.46)	0.03
Versican core protein	VCAN	P13611	0.93 (0.26–1.6)	0.06⁺	1.21 (0.44–1.97)	0.03
Trefoil factor 3	TFF3	Q07654	−0.92 (−1.63– −0.21)	0.095⁺	−1.19 (−1.99– −0.39)	0.04
Low-density lipoprotein receptor	LDLreceptor	P01130	−0.88 (−1.58– −0.19)	0.1⁺	−1.19 (−1.99– −0.38)	0.04

Cross-sectional associations between plasma proteins and FVC % predicted in EpiHealth before and after exclusion of individuals with known CVD, diabetes or obesity. Multivariable linear regression analysis for each protein. Data are regression coefficients for proteins increased by at least 1 standard deviation. Adjusted for age, sex, cohort, body mass index, smoking, pack-years and physical activity. For the sensitivity analysis this multivariable linear regression model was adjusted for hypertension, hyperlipidaemia and waist circumference (normal versus high) instead of BMI. FVC: forced vital capacity; CI: confidence interval; CVD: cardiovascular disease. ^#: n=2229; ^¶: n=1685; ⁺: non-significant.